Zobrazeno 1 - 10
of 216
pro vyhledávání: '"YOICHI NAITO"'
Autor:
Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Shogen Boku, Toshihiro Kudo, Yoshiyuki Yamamoto, Akiyoshi Kanazawa, Tadamichi Denda, Masahiro Goto, Naoko Iida, Hiroshi Ozaki, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Yoichi Naito, Takayuki Yoshino
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-10 (2024)
Abstract Background While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of
Externí odkaz:
https://doaj.org/article/8d89e02235024fa88d2552871e8438cb
Autor:
Takehiro Nakao, Kenichi Harano, Masashi Wakabayashi, Yoichi Naito, Hiroshi Tanabe, Toru Mukohara
Publikováno v:
Gynecologic Oncology Reports, Vol 55, Iss , Pp 101482- (2024)
Objective: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy rechallenge is considered; however, its efficacy after poly adenosine
Externí odkaz:
https://doaj.org/article/531ab3d12ed3433ea0a6a2a65cf6a74f
Autor:
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Background Retifanlimab is a humanized monoclonal antibody targeting programmed death protein‐1, and INCB001158 is an oral arginase inhibitor. This phase Ib study investigated retifanlimab, INCB001158, and their combination in Japanese pat
Externí odkaz:
https://doaj.org/article/054b73aa0e9c4d059dd35a08e6fa57cd
Autor:
Sonoko Misawa, Tadamichi Denda, Sho Kodama, Takuji Suzuki, Yoichi Naito, Takahiro Kogawa, Mamoru Takada, Tomoki Suichi, Kazuhito Shiosakai, Satoshi Kuwabara, on behalf of the MiroCIP study group
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is a painful, dose-limiting adverse effect of commonly used chemotherapeutic agents. The purpose of this exploratory study was to evaluate the efficacy and safety of mirogabalin in
Externí odkaz:
https://doaj.org/article/5c5d7bed96f94e5a8e4f6cacca56729a
Autor:
Kaede Baba, Megumi Kawamoto, Kanako Mamishin, Mao Uematsu, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Hiromichi Nakajima, Chikako Funasaka, Takehiro Nakao, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12095-12105 (2023)
Abstract Background Since it was first reported in December 2019, coronavirus disease 2019 (COVID‐19) spread rapidly across the globe resulting in a pandemic. As of August 2022, seven outbreak peaks have been confirmed in Tokyo, and the numbers of
Externí odkaz:
https://doaj.org/article/c0255b117bae403e9d5e854df13ba152
Autor:
Ryan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, Abner Herbert Lim, Seri Park, Yeon Hee Park, Ching-Hung Lin, Yen-Shen Lu, Makiko Ono, Takayuki Ueno, Yoichi Naito, Tatsuya Onishi, Geok-Hoon Lim, Su-Ming Tan, Han-Byoel Lee, Han Suk Ryu, Wonshik Han, Veronique Kiak Mien Tan, Fuh-Yong Wong, Seock-Ah Im, Puay Hoon Tan, Jason Yongsheng Chan, Yoon-Sim Yap
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-15 (2022)
Abstract Background HER2-low breast cancer (BC) is currently an area of active interest. This study evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-metastatic breast cancer (BC). Methods Patients with HER2-neg
Externí odkaz:
https://doaj.org/article/5bcb88b9c97b4e58a2441f664f3d4ca5
Autor:
Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii, Toru Mukohara
Publikováno v:
Breast, Vol 61, Iss , Pp 136-144 (2022)
Background: The previous second-line treatment for HER2-positive metastatic breast cancer were ado-trastuzumab emtansine (T-DM1); however, its activity is decreased in tumors with heterogenous, reduced, or loss of HER2 expression. Trastuzumab deruxte
Externí odkaz:
https://doaj.org/article/d024404aa0a9446f8558c9fcac6f4da6
Autor:
Toshihiko Doi, Noboru Yamamoto, Yoichi Naito, Yasutoshi Kuboki, Takafumi Koyama, Yongzhe Piao, Naoto Tsujimoto, Hiroya Asou, Koichi Inoue, Shunsuke Kondo
Publikováno v:
Cancer Medicine, Vol 10, Iss 19, Pp 6579-6589 (2021)
Abstract This phase 1, multi‐center, nonrandomized, open‐label, dose‐escalation study consisted of Part A wherein merestinib 80 or 120 mg (40‐mg tablets) was administered orally QD during a 28‐day cycle to patients diagnosed with solid tumo
Externí odkaz:
https://doaj.org/article/f41131648d9d4142aa9f53d94a51f451
Autor:
Chikako Funasaka, Yoichi Naito, Shota Kusuhara, Takehiro Nakao, Yoko Fukasawa, Kanako Mamishin, Ayumi Komuro, Mashiro Okunaka, Chihiro Kondoh, Kenichi Harano, Takahiro Kogawa, Nobuaki Matsubara, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Breast, Vol 58, Iss , Pp 50-56 (2021)
Background: Visceral crisis in metastatic breast cancer (MBC) is defined as severe organ dysfunction requiring rapidly efficacious therapy. Although weekly paclitaxel plus bevacizumab (wPTX + BV) achieves a high response rate in human epidermal growt
Externí odkaz:
https://doaj.org/article/1ee0cb78f98046edb5ecc170618af845
Autor:
Anjie Zhu, Peng Yuan, Nanlin Hu, Mingzhou Li, Wenmiao Wang, Xue Wang, Jian Yue, Jiayu Wang, Yang Luo, Fei Ma, Pin Zhang, Qing Li, Binghe Xu, Shanbo Cao, Giuseppe Lippi, Yoichi Naito, Mohammed A. Osman, Gustavo N. Marta, Gianluca Franceschini, Armando Orlandi
Publikováno v:
Cancer Biology & Medicine, Vol 18, Iss 3, Pp 875-887 (2021)
Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC.
Externí odkaz:
https://doaj.org/article/ff84631bd7354ef6954779789c081040